

ALLERGAN INC  
Form 425  
February 10, 2015

**Filing pursuant to Rule 425 under the  
Securities Act of 1933, as amended  
Deemed filed under Rule 14a-6(b) under the  
Securities Exchange Act of 1934, as amended**

**Filer: Allergan, Inc.**

**Subject Company: Allergan, Inc.**

**Form S-4 File No. 333-201242**

**Explanatory Note: The following contains a copy of the second issue of *Actavis + Allergan Integration Update*. A copy of the issue was attached to the below email sent to Allergan employees.**

**DATE:** February 9, 2015

**TO:** All Actavis and Allergan Employees

**RE:** **Actavis + Allergan Integration Update Issue #2**

We are pleased to share with you the second issue of the *Actavis + Allergan Integration Update*. In this issue, we highlight some of the work being done by the Pre-Integration Planning Teams, we define the concept of Growth Pharma and how the unique attributes of Actavis and Allergan would power the combined company, and we discuss some key next steps and dates.

Thank you for your patience and continued commitment to the separate Actavis and Allergan businesses. We will continue to keep you informed of additional milestones, decisions and next steps as we work to combine Actavis and Allergan.

**NOTE:** The attached publication is for Internal Use only. It is not for detailing or distribution outside the Company. Translated copies of this publication will be available shortly.





















